Dyne Therapeutics (DYN) PT Lowered to $45 at Morgan Stanley
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts DYN Hot Sheet
Price: $18.54 +2.71%
Rating Summary:
16 Buy, 2 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Rating Summary:
16 Buy, 2 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Join SI Premium – FREE
Morgan Stanley analyst Michael E Ulz lowered the price target on Dyne Therapeutics (NASDAQ: DYN) to $45.00 (from $47.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Novo Nordisk (NOVOB:DC) (NVO) PT Raised to DKK304 at Goldman Sachs
- FSN Ecommerce Ventures (FSNE:IN) PT Raised to INR300 at Goldman Sachs
- AppLovin Corp (APP) PT Raised to $445 at Goldman Sachs
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
